Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis".
- 1 December 2004
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 292 (21) , 2655
- https://doi.org/10.1001/jama.292.21.2655
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: